Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

The glob­al cell and gene ther­a­py (CGT) in­dus­try is poised for re­mark­able growth, dri­ven by sig­nif­i­cant ad­vances in life sci­ences and ro­bust in­vest­ments from cap­i­tal mar­kets. To strength­en this vi­tal sec­tor, Gen­Script is bring­ing to­geth­er lead­ing sci­en­tists, in­dus­try ex­perts, in­vestors, and reg­u­la­to­ry au­thor­i­ties at the Gen­Script Biotech Glob­al Fo­rum. This se­ries of con­fer­ences aims to ad­dress key in­dus­tri­al trends in cell ther­a­py and gene ther­a­py.

In the com­ing months, Gen­Script Biotech Glob­al Fo­rum will take place in Lon­don dur­ing the Jef­feries Lon­don Health­care Con­fer­ence on No­vem­ber 20, 2024 and at JP Mor­gan Health­care Con­fer­ence in San Fran­cis­co on Jan­u­ary 15, 2025.

High­lights from the Gen­Script Biotech Glob­al Forum Lon­don 2024

Sched­uled for No­vem­ber 20, 2024, dur­ing the Jef­feries Lon­don Health­care Con­fer­ence, this year’s fo­rum will ex­plore the theme “Un­lock the Full Po­ten­tial of Cell and Gene Ther­a­pies.” This event aims to fos­ter col­lab­o­ra­tion among in­dus­try lead­ers while tack­ling the chal­lenges and op­por­tu­ni­ties in the CGT land­scape.

Nav­i­gat­ing Chal­lenges: In­sights in­to the Fu­ture of CGT and Mul­ti­ple Cell Ther­a­py Tech­nolo­gies in De­vel­op­ment

In re­cent years, cell and gene ther­a­py has be­come a key play­er in bio­phar­ma­ceu­ti­cals, with a grow­ing num­ber of ap­provals an­nu­al­ly. CAR-T ther­a­pies are the most ad­vanced, while in­no­va­tions have led to a wider range of cell ther­a­pies, in­clud­ing CAR-NK, CAR-M, and TIL, ad­dress­ing var­i­ous chal­leng­ing dis­eases.

How­ev­er, the di­verse land­scape of new ther­a­pies and tech­nolo­gies presents nu­mer­ous chal­lenges. The fo­rum will fea­ture keynote speech­es from promi­nent fig­ures in cell and gene ther­a­py, in­clud­ing Dr. James M. Wil­son, Rose H. Weiss Pro­fes­sor and Di­rec­tor at Or­phan Dis­ease Cen­ter and Dr. Miguel Forte, Pres­i­dent of In­ter­na­tion­al So­ci­ety for Cell & Gene Ther­a­py (ISCT) and CEO of Ki­ji Ther­a­peu­tics.

In ad­di­tion, in­dus­try lead­ers such as Pas­cal Tou­chon, Chair­man of the Board, Atara Bio­ther­a­peu­tics, Biao Zheng, CEO of BRL Med­i­cine Inc, and Ja­son Fos­ter, CEO of Ori Biotech, will par­tic­i­pate in the pan­el dis­cus­sions ex­plor­ing the fu­ture of the CGT in­dus­try. Al­so, Dr. Ying Huang, CEO of Leg­end Biotech, the world’s high­est mar­ket val­ue CAR-T com­pa­ny, will share the sto­ry of Leg­end’s suc­cess.

In-Depth Dis­cus­sion on Gene Ther­a­py and mR­NA Vac­cines

The de­vel­op­ment of gene ther­a­py and mR­NA vac­cine tech­nolo­gies has been trans­for­ma­tive, es­pe­cial­ly dur­ing the COVID-19 pan­dem­ic. These in­no­va­tions al­so show great promise for rare dis­ease and ge­net­ic dis­or­ders. The fo­rum will ex­am­ine how ad­vance­ments in gene edit­ing are re­shap­ing clin­i­cal ap­pli­ca­tions. What in­no­va­tions are emerg­ing in the fields of gene ther­a­py and mR­NA vac­cines? What chal­lenges will arise as in­no­v­a­tive tech­nolo­gies tran­si­tion from R&D to clin­i­cal ap­pli­ca­tions? Deivi­das Paz­eraitis, Se­nior Sci­en­tist at As­traZeneca, Karim Ben­ab­del­lah, Prin­ci­pal In­ves­ti­ga­tor at GENYO, Pfiz­er/Uni­ver­si­ty of Grana­da/An­dalu­sian Re­gion­al Gov­ern­ment, and oth­er in­dus­tri­al lead­ers will share their in­sight on emerg­ing trends and chal­lenges as these tech­nolo­gies tran­si­tion from re­search to clin­i­cal ap­pli­ca­tions.

Ad­dress­ing CMC Chal­lenges in De­vel­op­ing and Man­u­fac­tur­ing CGT

Through­out the de­vel­op­ment and pro­duc­tion of cell and gene ther­a­pies, CMC chal­lenges abound. The qual­i­ty of raw ma­te­ri­als and the sta­bil­i­ty of sup­ply chains di­rect­ly im­pact the progress of ear­ly de­vel­op­ment. The com­plex­i­ty and con­sis­ten­cy con­trol of man­u­fac­tur­ing process­es from small-scale de­vel­op­ment to large-scale com­mer­cial­iza­tion re­main press­ing is­sues, with process scal­ing and stan­dard­iza­tion re­quir­ing fur­ther op­ti­miza­tion. Fur­ther­more, en­sur­ing prod­uct qual­i­ty and safe­ty in com­pli­ance with strin­gent reg­u­la­to­ry re­quire­ments is a per­sis­tent chal­lenge for suc­cess­ful mar­ket en­try.

The fo­rum will delve in­to mar­ket trends and fu­ture in­no­va­tion op­por­tu­ni­ties through pan­el dis­cus­sions. In­dus­try lead­ers such as Di­ma Al-Ha­dithi, CEO of Minaret Con­sult­ing Lim­it­ed, Pe­ter Jones, Di­rec­tor of Peng­win Con­sul­tan­cy, Ming Ewe, CEO of Smarter Biotech So­lu­tions, Jim Faulkn­er, CEO of JDB Bio­Con­sult­ing, and Arindam Mi­tra, CMC Di­rec­tor at Leu­cid Bio, will come to­geth­er to share strate­gies for over­com­ing cur­rent bot­tle­necks and dri­ving in­no­va­tion in CMC tech­nolo­gies, fa­cil­i­tat­ing faster and safer mar­ket en­try for CGT prod­ucts.

Ex­plor­ing the In­vest­ment Po­ten­tial of CGT: A Fu­ture Out­look

Cell and gene ther­a­pies have shown ex­cep­tion­al ef­fec­tive­ness in treat­ing a range of dis­eases, es­tab­lish­ing them as a sig­nif­i­cant trend in mod­ern health­care. As CGT moves in­to a rapid com­mer­cial­iza­tion phase, the sec­tor presents nu­mer­ous in­vest­ment op­por­tu­ni­ties, along with as­so­ci­at­ed risks and chal­lenges.

What chal­lenges do in­vest­ment re­turns in the CGT in­dus­try face? Where are the key in­vest­ment op­por­tu­ni­ties? How can in­sights at­tract fund­ing for pa­tient-ben­e­fit­ing so­lu­tions?

This fo­rum will fea­ture an in­vest­ment ses­sion pro­vid­ing in­sights from an in­vestor’s per­spec­tive, help­ing at­ten­dees un­der­stand CGT’s po­ten­tial while aim­ing for long-term re­turns as ther­a­pies progress to­ward com­mer­cial­iza­tion.

For more in­for­ma­tion, please vis­it the fo­rum web­site.

Reg­is­ter Now: https://bit.ly/477v0pa

Reg­is­ter us­ing code GSEP to re­serve your free pass (lim­it­ed to 20 tick­ets on­ly).

Up­com­ing Event: Gen­Script Biotech Glob­al Fo­rum 2025

Fol­low­ing the Lon­don fo­rum, the Gen­Script Biotech Glob­al Fo­rum 2025 is sched­uled for Jan­u­ary 15, 2025, at the San Fran­cis­co Mar­riott Mar­quis dur­ing the JP Mor­gan Health­care Con­fer­ence. This year’s theme, “Chal­lenges and Op­por­tu­ni­ties of Cell and Gene Ther­a­py in the New Era” will gath­er thought lead­ers from re­search, in­dus­try, and reg­u­la­to­ry bod­ies to dis­cuss the lat­est de­vel­op­ments shap­ing the fu­ture of CGT.

Fea­tured Keynote Speak­er:

Dr. Carl June, M.D.

Richard W. Vague, Pro­fes­sor in Im­munother­a­py and Di­rec­tor of the Cen­ter for Cel­lu­lar Im­munother­a­pies. Dr. June’s lab fo­cus­es on de­vel­op­ing in­no­v­a­tive CARs and vec­tors, ad­vanc­ing the field of can­cer ther­a­pies.

The agen­da will be re­leased soon.

For more in­for­ma­tion, please vis­it the fo­rum web­site.

The Gen­Script Biotech Glob­al Fo­rum se­ries rep­re­sents a crit­i­cal op­por­tu­ni­ty for stake­hold­ers across the CGT land­scape to en­gage, col­lab­o­rate, and dri­ve the next wave of in­no­va­tion in biotech­nol­o­gy. We look for­ward to wel­com­ing you in Lon­don and San Fran­cis­co as we col­lec­tive­ly ex­plore the chal­lenges and op­por­tu­ni­ties ahead in this dy­nam­ic field.

Reg­is­ter Now:

Gen­Script Biotech Glob­al Fo­rum Lon­don 2024: Un­lock the Full Po­ten­tial of Cell and Gene Ther­a­pies.

Lim­it­ed free pass­es are avail­able now. Click here to reg­is­ter us­ing code GSEP to se­cure your com­pli­men­ta­ry tick­et.

Gen­Script Biotech Glob­al Fo­rum 2025: Chal­lenges and Op­por­tu­ni­ties of Cell and Gene Ther­a­py in the New Era

Click here to reg­is­ter and se­cure your ear­ly-bird tick­et.

Con­tact Us: event@gen­script.com